Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 10/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 10/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.97 |
| ▸ | MAPT | P10636 | 3/20 | 0.97 |
| ▸ | GMNN | O75496 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indatraline SCHEMBL585770 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP3A4TP53 | |
| Indatraline SCHEMBL29516308 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP3A4TP53 | |
| Indatraline SCHEMBL11128740 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP3A4TP53 | |
| Indatraline SCHEMBL9252635 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP3A4TP53 | |
| (R,S)-Indatraline SCHEMBL31307192 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP3A4TP53 | |
| (R,S)-Indatraline SCHEMBL29516529 | 0.98 | MEN1 (1.00) | SLC6A2SLC6A4SLC6A3CYP3A4TP53 | |
| Indatraline SCHEMBL467134 | 0.98 | MEN1 (1.00) | SLC6A2SLC6A4SLC6A3CYP3A4TP53 | |
| Indatraline SCHEMBL5436564 | 0.98 | MEN1 (1.00) | SLC6A2SLC6A4SLC6A3CYP3A4TP53 | |
| Sertraline SCHEMBL3947169 | 0.87 | MEN1 (1.00) | SLC6A2SLC6A4SLC6A3CYP3A4TP53 | |
| Sertraline SCHEMBL137619 | 0.87 | MEN1 (1.00) | SLC6A2SLC6A4SLC6A3CYP3A4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4106872-A1 | COMPOSITIONS AND METHODS FOR ASSESSING THE EFFICACY OF INHIBITORS OF NEUROTRANSMITTER TRANSPORTERS | Denovo Biopharma LLC (US) | 2022-12-28 | — | — | EP | claimed |
| US-12612661-B2 | Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters | DENOVO BIOPHARMA, LLC (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4687890-A1 | METHODS FOR TREATING DEPRESSIVE STATES | BioXcel Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025003193-A1 | SERTRALINE AND INDATRALINE FOR DISRUPTING INTRACELLULAR CHOLESTEROL TRAFFICKING AND SUBSEQUENTLY INDUCING LYSOSOMAL DAMAGE AND ANTI-TUMOR IMMUNITY | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-01-02 | — | — | WO | disclosed |
| WO-2024211911-A1 | METHODS FOR TREATING DEPRESSIVE STATES | OAKTREE FUND ADMINISTRATION, LLC (US) | 2024-10-10 | — | — | WO | disclosed |
| US-20240018516-A1 | Agent for Regulating Expression and/or Function of RPS25 Gene | Sumitomo Pharma Co., Ltd. (JP) | 2024-01-18 | — | — | US | disclosed |
| US-20240018516-A1 | Agent for Regulating Expression and/or Function of RPS25 Gene | Sumitomo Pharma Co., Ltd. (JP) | 2024-01-18 | — | — | US | disclosed |
| EP-2911695-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON DISEASE BY THE SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC NEURON TYPES | PALOMO LTD (CY) | 2023-11-29 | — | — | EP | disclosed |
| EP-2911695-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON DISEASE BY THE SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC NEURON TYPES | PALOMO LTD (CY) | 2023-11-29 | — | — | EP | disclosed |
| US-20230372505-A1 | OLIGONUCLEIC ACID CONJUGATE | Sumitomo Pharma Co., Ltd. (JP) | 2023-11-23 | — | — | US | disclosed |
| WO-2014064257-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON DISEASE BY THE SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC NEURON TYPES | NLIFE THERAPEUTICS, S.L. (ES) | 2014-05-01 | — | — | WO | disclosed |
| US-20130251654-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AUTOPHAGY-RELATED DISEASES, ANGIOGENIC DISEASES OR MELANIN-RELATED DISEASES | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2013-09-26 | — | — | US | disclosed |
| US-20130251654-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AUTOPHAGY-RELATED DISEASES, ANGIOGENIC DISEASES OR MELANIN-RELATED DISEASES | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2013-09-26 | — | — | US | disclosed |
| US-20100292292-A1 | Treatment of Neurodegenerative Diseases Using Indatraline Analogs | LINK MEDICINE CORPORATION (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292292-A1 | Treatment of Neurodegenerative Diseases Using Indatraline Analogs | LINK MEDICINE CORPORATION (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2009036275-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES USING INDATRALINE ANALOGS | LINK MEDICINE CORPORATION (US) | 2009-03-19 | — | — | WO | disclosed |
| US-7385064-B1 | Catalysts for use in enantioselective synthesis | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2008-06-10 | — | — | US | disclosed |
| US-5447948-A | Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia | YALE UNIVERSITY (US) | 1995-09-05 | — | — | US | disclosed |
| US-5217987-A | Dopamine uptake inhibitors in reducing substance abuse and/or craving | BERGER STEPHEN P (US) | 1993-06-08 | — | — | US | disclosed |
| WO-1991011184-A1 | DOPAMINE UPTAKE INHIBITORS IN REDUCING SUBSTANCE ABUSE AND/OR CRAVING | YALE UNIVERSITY (US) | 1991-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612661-B2 | Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters | SLC6A4, SLC18A2, SLC6A2 | SLC6A2 3/4885SLC6A4 1/4885SLC6A3 5/4885 |
| US-20230372505-A1 | OLIGONUCLEIC ACID CONJUGATE | DCLRE1B, ANXA5, EEA1 | SLC6A2 751/4885SLC6A4 707/4885SLC6A3 1222/4885 |
| US-20240018516-A1 | Agent for Regulating Expression and/or Function of RPS25 Gene | RPS25, RPS26, RPS24 | SLC6A2 3379/4885SLC6A4 2596/4885SLC6A3 2173/4885 |
| US-20100292292-A1 | Treatment of Neurodegenerative Diseases Using Indatraline Analogs | HTT, SNCA, PARK7 | SLC6A2 19/4885SLC6A4 44/4885SLC6A3 8/4885 |
| US-20130251654-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AUTOPHAGY-RELATED DISEASES, ANGIOGENIC DISEASES OR MELANIN-RELATED DISEASES | ATG7, ATG13, BECN1 | SLC6A2 10/4885SLC6A4 37/4885SLC6A3 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.